A woman with FIGO stage III epithelial ovarian cancer is being discussed by the specialist gynaecological multidisciplinary team. She is suitable for either primary cytoreductive surgery followed by platinum-based chemotherapy or platinum-based neoadjuvant chemotherapy followed by interval cytoreductive surgery.
What does the evidence in this Cochrane review support when comparing neoadjuvant chemotherapy with primary cytoreductive surgery in advanced epithelial ovarian cancer?